Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RARE · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
24
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Ultragenyx Pharmaceutical Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
RARE insider buying and selling by quarter
RARE insider selling · RARE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · RARE ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
RARE executive sell shares · RARE board member insider trading · RARE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Horn Howard CFO | Sale | 4,653 | $111K | Form 4 |
| May 14, 2026 | Fust Matthew K Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | SULIMAN SHEHNAAZ Director | Award | 7,751 | — | Form 4 |
| May 18, 2026 | SULIMAN SHEHNAAZ Director | Sale | 5,740 | $144K | Form 4 |
| May 14, 2026 | Ray Amrit Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | Sanders Corazon (Corsee) D. Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | NARACHI MICHAEL Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | WELCH DANIEL G Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | Dunsire Deborah Director | Award | 7,751 | — | Form 4 |
| May 5, 2026 | Crombez Eric EVP and Chief Medical Officer | Sale | 344 | $9K | Form 4 |
| May 1, 2026 | Horn Howard CFO | Sale | 4,683 | $117K | Form 4 |
| Apr 22, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Award | 20,241 | — | Form 4 |
| Apr 16, 2026 | KAKKIS EMIL D President & CEO · Director | Award | 76,745 | — | Form 4 |
| Apr 16, 2026 | Huang Dennis Karl See Remarks | Award | 23,116 | — | Form 4 |
| Apr 16, 2026 | Pinion John Richard See Remarks | Award | 23,116 | — | Form 4 |
| Apr 16, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Award | 28,895 | — | Form 4 |
| Apr 16, 2026 | Harris Erik EVP & Chief Commercial Officer | Award | 28,895 | — | Form 4 |
| Apr 16, 2026 | Crombez Eric EVP and Chief Medical Officer | Award | 34,674 | — | Form 4 |
| Apr 16, 2026 | Horn Howard CFO | Award | 34,674 | — | Form 4 |
| Apr 1, 2026 | Horn Howard CFO | Sale | 4,683 | $98K | Form 4 |
| Mar 6, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 6,018 | $129K | Form 4 |
| Mar 10, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 3,508 | $80K | Form 4 |
| Mar 1, 2026 | Pinion John Richard See Remarks | Award | 11,137 | — | Form 4 |
| Mar 2, 2026 | Pinion John Richard See Remarks | Sale | 10,029 | $229K | Form 4 |
| Mar 1, 2026 | Harris Erik EVP & Chief Commercial Officer | Award | 11,643 | — | Form 4 |
Crombez Eric
EVP and Chief Medical Officer
Date
May 5
Shares
344
Price
$24.96
Value
$9K
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Date
Apr 22
Shares
20,241
Price
—
Value
—
KAKKIS EMIL D
President & CEO · Director
Date
Apr 16
Shares
76,745
Price
—
Value
—
Parschauer Karah Herdman
EVP and Chief Legal Officer
Date
Apr 16
Shares
28,895
Price
—
Value
—
Harris Erik
EVP & Chief Commercial Officer
Date
Apr 16
Shares
28,895
Price
—
Value
—
Crombez Eric
EVP and Chief Medical Officer
Date
Apr 16
Shares
34,674
Price
—
Value
—
Parschauer Karah Herdman
EVP and Chief Legal Officer
Date
Mar 6
Shares
6,018
Price
$21.40
Value
$129K
Parschauer Karah Herdman
EVP and Chief Legal Officer
Date
Mar 10
Shares
3,508
Price
$22.67
Value
$80K
Harris Erik
EVP & Chief Commercial Officer
Date
Mar 1
Shares
11,643
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RARE insider trading
RARE insider trades
Ultragenyx Pharmaceutical Inc. (RARE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Horn Howard (CFO), Huizenga Theodore Alan (SVP, Chief Accounting Officer), Parschauer Karah Herdman (EVP and Chief Legal Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. RARE insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Ultragenyx Pharmaceutical Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RARE insider trading · 5 questionsThe insiders of Ultragenyx Pharmaceutical Inc. (RARE) include executives and directors such as Horn Howard (CFO), Huizenga Theodore Alan (SVP, Chief Accounting Officer), Parschauer Karah Herdman (EVP and Chief Legal Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026